Sponsored Links
| Vion Pharmaceuticals Receives Response From FDA On Special Protocol Assessment For Onrigin(TM) |
 |
 |
 |
| Pharmacy - Pharma Industry - Biotech Industry | |||
|
VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VIONQ) announced that it had received a response from the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment ("SPA") for its oncology therapeutic Onrigin™ (laromustine) Injection... Read more: Pharma Industry / Biotech Industry News From Medical News Today
|